These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 3319458)

  • 1. Pharmacology and pharmacokinetics of 5-aminosalicylic acid.
    Klotz U; Maier KE
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):46S-50S. PubMed ID: 3319458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update.
    Martin F
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):57S-63S. PubMed ID: 2891469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oroileal transit of slow release 5-aminosalicylic acid.
    Goebell H; Klotz U; Nehlsen B; Layer P
    Gut; 1993 May; 34(5):669-75. PubMed ID: 8504969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol Suppl; 1988; 148():54-9. PubMed ID: 2906478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
    Thomson AB
    Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
    Gionchetti P; Campieri M; Belluzzi A; Boschi S; Brignola C; Miglioli M; Barbara L
    Aliment Pharmacol Ther; 1994 Oct; 8(5):535-40. PubMed ID: 7865646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
    Healey JN
    Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission.
    Almer S; Norlander B; Ström M; Osterwald H
    Scand J Gastroenterol; 1991 Mar; 26(3):327-35. PubMed ID: 1853156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological bases of therapy with 5-ASA].
    Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
    Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease.
    Sonu I; Lin MV; Blonski W; Lichtenstein GR
    Gastroenterol Clin North Am; 2010 Sep; 39(3):559-99. PubMed ID: 20951918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review].
    Van Gossum A
    Acta Gastroenterol Belg; 1992; 55(5-6):462-71. PubMed ID: 1363167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible mode of action of 5-aminosalicylic acid.
    Peskar BM; Dreyling KW; May B; Schaarschmidt K; Goebell H
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):51S-56S. PubMed ID: 2891468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfasalazine and 5-ASA compounds.
    Allgayer H
    Gastroenterol Clin North Am; 1992 Sep; 21(3):643-58. PubMed ID: 1355468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
    Robinson MG
    Gastroenterol Clin North Am; 1989 Mar; 18(1):43-50. PubMed ID: 2646221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
    Maier K; Fischer C; Klotz U; Heinkel K
    Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1990 Oct; 4(5):497-505. PubMed ID: 2129637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical salicylate therapy (4-ASA and 5-ASA enemas).
    Ginsberg AL
    Gastroenterol Clin North Am; 1989 Mar; 18(1):35-42. PubMed ID: 2563990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE; Schraa CC
    Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.